Latest Acute myeloid leukemia Stories
ATLANTA, Dec. 9, 2012 /PRNewswire-USNewswire/ -- Encouraging safety and efficacy data on novel and emerging therapies presented at the 54th Annual Meeting of the American Society of Hematology (ASH) signal an important step forward in the development of treatment strategies for patients with hard-to-treat leukemia, myeloma, and myelofibrosis. Ongoing discoveries of critical molecular markers, pathways, and other drivers of some of the most difficult-to-treat forms of blood cancer...
ATLANTA, Dec. 8, 2012 /PRNewswire-USNewswire/ -- Research identifying genetic factors that affect survival of patients with blood cancers and evaluating the effectiveness of modified treatment strategies to improve outcomes while reducing toxicity will be presented today at the 54th Annual Meeting of the American Society of Hematology (ASH). While the cancer research community has seen many significant therapeutic advances over the last decade, only recently have investigators...
BLUE BELL, Pa., Dec. 6, 2012 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) announced today that preliminary results of a phase II clinical trial to treat leukemia with a WT1 DNA vaccine delivered with Inovio's proprietary electroporation delivery system showed robust vaccine-specific antibody responses in all vaccinated subjects evaluated to date. Furthermore, T cell immune responses, including those of the "killer T cells," were detected. Antibody and T cell responses...
WHITE PLAINS, N.Y. and STANFORD, Calif., Dec. 5, 2012 /PRNewswire/ -- Stanford University School of Medicine has presented John Walter, CEO of The Leukemia & Lymphoma Society (LLS), with the 2012 Spirit of Hope Award for Outstanding Health Care Organization in recognition of LLS's 35 years of funding support to Stanford's researchers. (Photo: http://photos.prnewswire.com/prnh/20121205/NY24577 ) In the last 15 years alone, LLS has awarded more than $27 million in research grants...
NEW YORK, Dec. 5, 2012 /PRNewswire/ -- Actinium Pharmaceuticals reported today that data from two abstracts of studies investigating the company's pipeline hematology product Iomab-B will be presented at the American Society of Hematology's (ASH) 54th Annual Meeting and Exposition in Atlanta (December 8-11, 2012). These abstracts include summaries of data from studies in acute myelogenous leukemia, myelodysplastic syndrome (MDS) and acute lymphocytic leukemia (ALL). Studies...
WHITE PLAINS, N.Y., Dec. 4, 2012 /PRNewswire/ -- The Leukemia & Lymphoma Society (LLS) has issued new requests for proposals from researchers in six critical areas of unmet medical need. The RFPs mark LLS's aggressive and proactive approach to addressing the challenge of improving outcomes for cancer patients with particularly urgent needs. LLS aims to stimulate more academic research in these areas: New immunotherapeutics for patients with acute myelogenous leukemia; Novel...
RIDGEFIELD, Conn., Nov. 29, 2012 /PRNewswire/ -- Boehringer Ingelheim today announced that new data evaluating volasertib, an investigational polo-like kinase (Plk) inhibitor, will be presented at the 54(th) American Society of Hematology (ASH) annual meeting taking place December 8-11 in Atlanta, Ga. Data include results from the Phase II portion of a Phase I/II study evaluating volasertib administered in addition to low-dose cytarabine (LDAC) compared to LDAC...
A new study has found Acute Myeloid Leukaemia (AML) patients given a new type of 'smart drug' in addition to chemotherapy treatment are 22 per cent less likely to relapse and around 13 per cent less likely to die from their disease. The results are from a major phase III Cancer Research UK-funded trial led by Cardiff University. Of the 1,115 patients who took part in the trial, 68 per cent relapsed on the new treatment within three years, compared with 76 per cent of those who had the...
MEMPHIS, Tenn., Nov. 12, 2012 /PRNewswire/ -- Research led by the St. Jude Children's Research Hospital - Washington University Pediatric Cancer Genome Project has identified a fusion gene responsible for almost 30 percent of a rare subtype of childhood leukemia with an extremely poor prognosis. To view the multimedia assets associated with this release, please click: http://www.multivu.com/mnr/58586-st-jude-children-s-research-hospital-gene-sequencing-childhood-leukemia The...
NEW YORK, Nov. 8, 2012 /PRNewswire/ -- Stemline Therapeutics, Inc., a clinical-stage biopharmaceutical company developing oncology therapeutics that target both cancer stem cells (CSCs) and tumor bulk, announced today that a heavily pre-treated patient with a drug-refractory and recurrent blastic plasmacytoid dendritic cell neoplasm (BPDCN) achieved a complete response (CR) following treatment with Stemline's SL-401. BPDCN is a rare and aggressive hematologic cancer which is...
